{
  "id": "60274ec61cb411341a0000e5",
  "type": "list",
  "question": "Which drugs are included in the VAC regiment for Ewing's sarcoma?",
  "ideal_answer": "VAC regiment for Ewing's sarcoma includes vincristine, actinomycin, cyclophosphamide.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/991106",
    "http://www.ncbi.nlm.nih.gov/pubmed/14521810",
    "http://www.ncbi.nlm.nih.gov/pubmed/7029293",
    "http://www.ncbi.nlm.nih.gov/pubmed/12441260",
    "http://www.ncbi.nlm.nih.gov/pubmed/31197128",
    "http://www.ncbi.nlm.nih.gov/pubmed/11531770",
    "http://www.ncbi.nlm.nih.gov/pubmed/7583389",
    "http://www.ncbi.nlm.nih.gov/pubmed/29541566",
    "http://www.ncbi.nlm.nih.gov/pubmed/15626016",
    "http://www.ncbi.nlm.nih.gov/pubmed/20110048",
    "http://www.ncbi.nlm.nih.gov/pubmed/15613556",
    "http://www.ncbi.nlm.nih.gov/pubmed/10742059",
    "http://www.ncbi.nlm.nih.gov/pubmed/2667789",
    "http://www.ncbi.nlm.nih.gov/pubmed/9053479",
    "http://www.ncbi.nlm.nih.gov/pubmed/26271204",
    "http://www.ncbi.nlm.nih.gov/pubmed/2016622"
  ],
  "snippets": [
    {
      "text": "All underwent surgical exploration with a laminectomy and partial resection followed by adjuvant radiotherapy to a dose of 46-50 Gy and chemotherapy with VAC (vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at least six cycles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11531770",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combination of vincristine, dactinomycin, cyclophosphamide (VAC), and XRT did not significantly improve survival in 39 patients (62% alive at 10 years) compared with that of 24 patients treated with VAC and XRT without DOX (65% alive at 10 years, P = .93).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9053479",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with tumors in clinical groups II, III, and IV were treated with radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide (VAC) +/- doxorubicin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2016622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite numerous molecular and biological studies during the past three decades, the chemotherapeutic regimen remains unchanged. This vincristine, actinomycin, cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al. (1963), has achieved limited success in controlling the progression of RMS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29541566",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After the induction chemotherapy consisting of alternating vincristine, adriablastin, cyclophosphamide (VAC) and etoposide, ifosfamide with mesna protection (IE), a local treatment modality was chosen based on tumor and patient characteristics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15613556",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Induction chemotherapy consisted of two cycles of 'VAC': vincristine (V), doxorubicin (A), cyclophosphamide (C) alternated with one cycle of 'VIAc': V, ifosfamide (I), actinomycin (Ac). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12441260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II studies using ifosfamide both alone and combined with vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin) therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2667789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase II studies using ifosfamide both alone and combined with vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin) therapy. In Novembe",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2667789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271204",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vincristine, actinomycin D, and cyclophosphamide (VAC) were administered to 14 patients with Ewing's sarcoma. The pr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/991106",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Every patient received both types of G-CSF in different treatment courses of chemotherapy, which consisted of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE); vincristine, actinomycin D, and ifosfamide (VAI); or vincristine, actinomycin D, and cyclophosphamide (VAC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110048",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "VAC (vincristine, actinomycin D, and cyclophosphamide) regimens with anthracyclines resulted in better survival. Presence of distant metastases, large primary tumors, and pelvic localization were related to poor prognosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15626016",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The effective treatment for sarcoma botryoides is wide excision with safe margin of 1-2 cm, followed by 6-12 cycles of vincristine, actinomycin D, and cyclophosphamide (VAC) regiment as an adjuvant chemotherapy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31197128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7583389",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7583389",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PROCEDURE: Standard chemotherapy consisted of etoposide/ifosfamide (VP16/IFOS) cycles, alternating with vincristine/dactinomycin/cyclophosphamide (VAC) cycles. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10742059",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Intergroup Study was designed to determine if the addition of adriamycin (ADR) or bilateral pulmonary radiotherapy (RT) to vincristine, dactinomycin, and cyclophosphamide (VAC therapy) would improve survival and reduce local recurrences and metastases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7029293",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VAC) by Dr. Ruth Heyn, Dr. Harold Mauer and colleagues developed a more robust VAC as well as three similar drug regimens with hematopoietic growth factor support, which, in the context of surgery with or without radiotherapy, achieved a 3-year failure-free survival rate of 83% (IRS-IV) in nonmetastatic embryonal rhabdomyosarcoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14521810",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "vincristine, actinomycin, cyclophosphamide"
}